ERBB2 and Ewing sarcoma: Encouraging outcomes were demonstrated in a phase I/II clinical study (NCT00902044) using human epidermal growth factor receptor-2 (HER2)-CAR-T cells in the treatment of 19 patients with HER2-positive sarcomas (16 osteosarcomas, 1 primitive neuroectodermal, 1 Ewing sarcoma, and 1 protofibroblastic small round cell tumor) [39].